Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus Clinical Trial

Official title:

A Preliminary Safety and Efficacy Evaluation of Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Mellitus (T1DM) Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03484741
• Other study ID #: DIME 1001
• Secondary ID: DIME 1001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• First received: March 16, 2018
• Last updated: April 2, 2018
• Start date: April 1, 2017
• Est. completion date: November 2018

Study information

• Verified date: April 2018
• Source: Van Hanh General Hospital
• Contact: Phuong Le, MSc-MD
• Phone: (+84)902742732
• Email: drbphuong[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) transplantation for type 1 Diabetes Mellitus patients.

Description:

Mesenchymal stem cells (MSCs) are collected from autologous bone marrow mononuclear cells and allogeneic umbilical cord tissue (UC-MSC).

15 patients with type 1 Diabetes Mellitus will be enrolled and will receive MSCs by intravenous infusion. They were followed up for 6 months after transplantation.

Safety is to assess the occurrence of adverse events (AEs) during either stem cells infusion or by physician assessments.

The primary endpoint is to assess the improvement of patients' Fasting blood glucose, HbA1C, C-peptide, and blood insulin level.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: November 2018
• Est. primary completion date: November 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Who is diagnosed with Type 1 Diabetes Mellitus according to the ADA, the patients meet at least one of the following criteria:

• At least one autoantibody associated with Type 1 Diabetes Mellitus such as ICA or GAD.

• Previously diagnosed at a medical facility with Type 1 Diabetes.

• Having evidence of insulin depletion based on the test results during screening.

• Patients treated with fixed insulin dose for at least 3 months.

• Males and females between age 18 and 45 years at the screening.

• Patients able to read, write and understand ICF form

Exclusion Criteria:

• Uncontrolled blood pressure at the time of enrollment: systolic pressure >160 mmHg and/or diastolic blood pressure > 100 mmHg.

• Having evidence related to renal dysfunction:

• creatinine > 1.5 mg/dl or (>133 mmol/L) for men.

• creatinine > 1.4 mg/dl or (>124 mmol/L) for woman.

• eGRF < 40 ml/ min

• Proteinuria > 300 mg/day

• Having evidence of ketoacidosis at the time of selection.

• Having evidence of ongoing or frequent hypoglycemia.

• Having severe infection

• Infected with hepatitis B virus or hepatitis C or tuberculosis. Positive results of HbsAg or Anti HCV or/and PCR tuberculosis are only acceptable in case of vaccination and without suspicious signs. All other cases are not accepted even in the absence of clinical signs.

• Diseases detected before/during screening such as cardiovascular disease, respiratory disease ( pulmonary, fibrosis, chronic respiratory failure), liver disease, cancer, neurology, metabolism.

• Having abnormalities in red blood cells such as sickle cells disease.

• Using alcohol and/or tobacco.

• Blood clotting disorders (INR > 1.5, PTT >40, PT > 15).

• Taking any anticoagulant.

• Taking systemic steroids.

• Participate in another clinical study involving experimenting drugs and/or medical equipment.

• Patients who are unable to perform the tests and assessments needed for the study (eg, patients who are unable to perform bone marrow transplantation) or patients who do not agree to participate in the study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Biological:
• MSC and PRP
MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.

Locations

Country	Name	City	State
Vietnam	Van Hanh Geral Hospital	Ho Chi Minh City	Ho Chi Minh

Sponsors (2)

Lead Sponsor	Collaborator
Van Hanh General Hospital	University of Science Ho Chi Minh City

Country where clinical trial is conducted

Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fasting blood glucose	Assess the changes in fasting blood glucose level after transplantation	every month in the course of 6 months
Primary	Hemoglobin A1c (HbA1c) level	Assess the changes in HbA1C level after transplantation	1 month, 3 months and 6 months after transplantation
Primary	Adverse events	Evaluate the safety of therapy by number record of adverse events (AEs)	during the course of 6 months
Secondary	Insulin dose	Reduction of insulin dose after transplantation	during the course of 6 months
Secondary	C-peptide	Assess the improvement in C-peptide level after transplantation	every month in the course of 6 months
Secondary	Blood insulin level	Assess the changes in blood insulin level after transplantation	every month in the course of 6 months